Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on November 18, 2024, the Compensation Committee of Vera's Board of Directors granted inducement awards consisting of a non-qualified stock option to purchase 108,000 shares of Class A common stock and restricted stock units (RSUs) for 53,000 shares of Class A common stock to Jason S. Carter, Vera's new Chief Legal Officer, under Vera's 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4).
BRISBANE,加州，2024年11月22日(GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (纳斯达克: VERA) 今天宣布，2024年11月18日，Vera的董事会的薪酬委员会授予了引诱奖，包括一项非合格股票期权，以购买10.8万股A类普通股和5.3万股A类普通股的限制股票单位（RSUs）给Jason S. Carter，Vera的新首席法务官，根据Vera的2024年引诱计划。 薪酬委员会批准了奖励，作为符合纳斯达克上市规则5635(c)(4)的新员工就业的引诱材料。
The stock option granted on November 18, 2024 has an exercise price per share equal to $44.81, Vera's closing trading price on November 18, 2024. Each stock option will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee's continued service relationship with Vera through the applicable vesting dates. Each of the RSUs will vest over four years, with 25% of the underlying shares vesting on each anniversary of November 20, 2024, subject to the new employee's continued service relationship with Vera through the applicable vesting dates. The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
2024年11月18日授予的股票期权每股的行权价为44.81美元，与Vera在2024年11月18日的收盘交易价格相等。每个股票期权将在四年内分批授予，其中25%的基础股票将在适用授予开始日期的第一周年日行权，其余基础股票将在此后36个月内每月分批行权，在新员工通过适用的行权日期与Vera的持续服务关系的情况下。每个RSU将在四年内分批授予，其中25%的基础股票将于2024年11月20日的每个周年日行权，而新员工有责继续通过适用的行权日期与Vera的持续服务关系。奖励受引诱计划的条款和条件以及涵盖授予的适用奖励协议的条款和条件约束。
About Vera
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera's mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger's disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit .
维拉治疗是一家专注于开发治疗严重免疫性疾病的后期临床阶段生物技术公司。维拉的使命是推动针对免疫性疾病的治疗手段，以改变患者的治疗标准。维拉的首席产品候选人是atacicept，一种融合蛋白，每周自行皮下注射一次，可阻断激活B细胞的因子（BAFF）和促进增生的配体（APRIL），这些会刺激B细胞和浆细胞产生自身抗体，导致某些自身免疫性疾病，包括IgAN，又称伯杰氏病和狼疮性肾炎。此外，维拉正在评估更多的疾病，atacicept可通过降低自身抗体来证明其在医学上的可用性。维拉还在开发MAU868，一种单克隆抗体，旨在中和与BK病毒（BKV）感染，这是一种多瘤病毒，其在某些情况下（例如肾移植）可能会产生毁灭性后果。维拉保留atacicept和MAU868的所有全球开发和商业化权利。有关更多信息，请访问。
Vera Therapeutics是一家致力于开发治疗严重免疫性疾病的后期临床生物技术公司，旨在开发针对免疫性疾病源头的治疗方法，以改变患者的治疗标准。Vera的领先产品候选者是atacicept，它是一种融合蛋白，每周一次通过皮下注射进行自我管理，可以阻止B细胞活化因子（BAFF）和增殖诱导配体（APRIL）的活性，这两种对某些自身免疫性疾病，包括肾IgA肾病（IgAN，又称Berger病）和狼疮性肾炎的自身抗体制造B细胞和浆细胞具有贡献作用。此外，维拉也正在评估其他减少atacicept中自身抗体作用可能在医学上证明有用的疾病。维拉还正在开发MAU868，这是一种单克隆抗体，旨在中和BK病毒(BKV)感染，BK病毒是一种多种病毒，在某些情况下，例如肾移植中可能会有灾难性后果。维拉保留atacicept和MAU868的全球开发和商业权利。有关更多信息，请访问网站。
For more information, please contact:
更多信息，请联系:
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
投资者联系人：
乔伊斯·阿莱尔
LifeSci顾问
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Madelin Hawtin
LifeSci Communications
MHawtin@lifescicomms.com
媒体联系：
Madelin Hawtin
通信-半导体
MHawtin@lifescicomms.com